The Seglin platform has been extensively validated and a number of small molecule, orally bioavailable Seglin compounds have been identified across multiple therapy areas, including ones against previously intractable targets.
Summit’s internal research is currently focussed in the high-value therapy areas of Type II diabetes and infectious diseases and the Company will further exploit the technology’s wider potential through strategic alliances.
